Kāhu SiliconBio secured a £1.2 million grant from the German Federal Agency for Disruptive Innovation (SPRIN-D) to advance its continuous hormone monitoring technology for women’s health conditions.
Co-founded by Dr. James Flewellen and Professor Teuta Pilizota, the University of Edinburgh spinout is commercializing biosensor technology designed to continuously measure hormone levels throughout the day.
While traditional hormone tests capture one-off measurements, Kāhu’s technology continuously tracks hormone fluctuations–connecting levels to sleep, stress, nutrition, and menstrual cycle changes over time.
Initially designed for general hormone tracking, Kāhu will use the latest funding to develop its next prototype, focusing on women’s health applications, while growing its team, advancing research, and establishing clinical partnerships.
Alongside Kāhu, several brands are rethinking hormone testing. Eli Health offers rapid at-home saliva tests, Perperity Health measures hormones in sweat, and Mira’s taps into urine samples. Preparing to launch, Clair Health is bringing its wrist-worn monitor to market this fall. With real-time analytics, these companies aim to establish new diagnostic standards for conditions impacted by hormonal imbalances, like PMOS, endometriosis, and infertility.
